Guselkumab Effective After TNF Inhibitor Failure in PsA

Published Date: 14 Mar 2026

Guselkumab, administered every 4 or 8 weeks, is effective and safe in patients with active psoriatic arthritis who have had an inadequate response to only one prior TNF inhibitor.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Relationship-building key to addressing oncologist shortages in rural care

2.

New protein target discovered for childhood medulloblastomas

3.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

4.

Papillary thyroid cancer: New markers offer hope for tailored treatment

5.

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot